2022
Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis
Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, Goldstein L, Saliba W. Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis. Clinical Infectious Diseases 2022, 76: 453-460. PMID: 36130189, DOI: 10.1093/cid/ciac781.Peer-Reviewed Original ResearchConceptsSevere COVID-19Composite outcomeSevere acute respiratory syndrome coronavirus 2COVID-19-specific mortalityModerate coronavirus disease 2019Acute respiratory syndrome coronavirus 2Propensity Score Matched AnalysisCOVID-19-related mortalityCOVID-19Respiratory syndrome coronavirus 2High-risk patientsTreatment of mildSyndrome coronavirus 2Emergency use authorizationCoronavirus disease 2019Largest healthcare providerHazard ratioVaccination statusMatched AnalysisCoronavirus 2Subgroup analysisDisease 2019High riskPositive testPatientsImmunity waning after COVID vaccine booster vs. infection—better than expected
Khoury J, Najjar-Debbiny R, Elemy A, Jabbour A, Haj J, Abu-Sini M, Yasin R, Amin M, Hellou E, Nasrallah N, Saffouri A, Hakim F. Immunity waning after COVID vaccine booster vs. infection—better than expected. Infectious Diseases 2022, 54: 828-831. PMID: 35796285, DOI: 10.1080/23744235.2022.2097304.Peer-Reviewed Original ResearchMeSH KeywordsBNT162 VaccineCOVID-19COVID-19 VaccinesHumansImmunization, SecondaryProspective StudiesConceptsBooster doseSecond doseThird doseSecond boosterBNT162b2 mRNA COVID-19 vaccineMRNA COVID-19 vaccineCOVID-19 PCRIgG antibody titresBAU/mLCOVID-19 vaccineEMMS Nazareth HospitalVaccine boosterSuggestive symptomsMean titresNasopharyngeal swabsProspective studyAsymptomatic infectionDoses groupsAntibody titresBooster groupGeneral populationHigh titresDoseTitresDosesEffectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients
Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, Goldstein L, Saliba W. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clinical Infectious Diseases 2022, 76: e342-e349. PMID: 35653428, PMCID: PMC9214014, DOI: 10.1093/cid/ciac443.Peer-Reviewed Original ResearchConceptsSevere COVID-19COVID-19 vaccination statusVaccination statusHazard ratioCOVID-19Severe acute respiratory syndrome coronavirus 2High-risk patients trialModerate coronavirus disease 2019Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Adjusted hazard ratioHigh-risk patientsTreatment of mildCox hazard regressionSyndrome coronavirus 2Emergency use authorizationCoronavirus disease 2019Largest healthcare providerEligible patientsOlder patientsRisk patientsHazards regressionCoronavirus 2Cardiovascular diseaseTime-dependent variables
2021
COVID-19 vaccine – Long term immune decline and breakthrough infections
Khoury J, Najjar-Debbiny R, Hanna A, Jabbour A, Abu Ahmad Y, Saffuri A, Abu-Sinni M, Shkeiri R, Elemy A, Hakim F. COVID-19 vaccine – Long term immune decline and breakthrough infections. Vaccine 2021, 39: 6984-6989. PMID: 34763949, PMCID: PMC8556595, DOI: 10.1016/j.vaccine.2021.10.038.Peer-Reviewed Original ResearchMeSH KeywordsBNT162 VaccineCOVID-19COVID-19 VaccinesHumansImmunogenicity, VaccineProspective StudiesSARS-CoV-2ConceptsAntibody titersCOVID-19 vaccineBreakthrough infectionsSecond doseAntibody levelsPolymerase chain reactionBNT162b2 mRNA COVID-19 vaccineSARS-CoV-2 polymerase chain reactionMRNA COVID-19 vaccineStudy periodBreakthrough infection rateMedian antibody levelsMean antibody levelsLongitudinal prospective studyAntibody declineTiter elevationImmune declineProspective studyClinical indicationsMild casesHealthcare personnelInfection rateInfectionVaccinePeak levels